公司概述
Karyopharm Therapeutics Inc. operates as a commercial-stage pharmaceutical entity focused on the discovery, development, and commercialization of drugs targeting nuclear export mechanisms for treating cancer and other diseases within the United States, utilizing novel and small molecule compounds. The company functions within the healthcare sector, specifically the biotechnology industry, which implies a reliance on rigorous research and development cycles and regulatory approval processes before products reach the market. In terms of scale, the entity holds a market capitalization of $183.95M, generates annual revenue of $146.07M, and employs a workforce of 228 individuals. These valuation and revenue figures indicate that the company operates as a mid-cap biotechnology firm with significant revenue generation relative to its market size, yet the market capitalization suggests investors are pricing the stock with caution, likely reflecting the high-risk nature of the biotech sector where future earnings potential is heavily dependent on the successful commercialization of its pipeline.
财务健康
The company reported a trailing twelve-month revenue of $146.07M, while simultaneously posting a net income loss of $-196,039,008 and an EBITDA of $-90,411,000. The substantial gap between positive revenue and negative net income reveals a highly leveraged cost structure where operating expenses, likely dominated by research and development or commercialization costs, exceed gross margins significantly. Free cash flow stands at $-49,426,500, indicating that the company is currently burning cash, which limits its financial flexibility and necessitates reliance on external capital sources or existing cash reserves to fund operations. Profitability analysis shows a gross margin of 9.9%, an operating margin of -52.4%, and a profit margin of -134.2%, where the negative operating and profit margins indicate that the company is not generating sufficient profit from its core operations to cover its fixed costs or generate returns for shareholders. On the balance sheet, cash holdings of $63.74M are significantly lower than total debt of $305.94M, and with a debt-to-equity ratio listed as N/A due to the financial structure, the company appears highly leveraged rather than conservative. Liquidity is assessed by a current ratio of 1.12, which indicates that the company's current assets are only slightly higher than its current liabilities, suggesting a tight but technically sufficient short-term liquidity position. Return on Equity is N/A, while Return on Assets is -41.6%, revealing that management is currently utilizing the company's asset base to generate losses rather than positive returns.
估值评估
Valuation metrics present a challenging picture, with a trailing P/E ratio of N/A and a forward P/E of -1.87, implying that the market cannot value the stock based on historical earnings and expects earnings to remain negative or volatile in the near term. The price-to-book ratio is -0.51, which indicates that the stock is trading below its book value, a situation often seen in distressed or unprofitable biotech firms where assets may not be fully valued or liabilities are substantial. Alternative valuation metrics include a price-to-sales ratio of 1.26 and an EV/EBITDA of -4.33, suggesting that investors are pricing the company primarily on its sales potential rather than profitability or earnings power. Price action shows a 52-week high of $10.99 and a 52-week low of $3.65; without a specific current price provided in the facts, the valuation relative to this range remains undefined by the available data, but the wide range suggests high price instability. The stock exhibits a beta of 0.40, which means the stock's price volatility is significantly lower than the broader market, indicating that the company's share price is less sensitive to general market movements compared to large-cap indices.
Growth & Income
Revenue growth year-over-year is recorded at 11.6%, while earnings growth year-over-year is N/A, indicating that while top-line sales are expanding, profitability has not yet materialized to allow for meaningful earnings growth calculations. Since the earnings growth metric is unavailable and the company reports significant net losses, the traditional comparison of earnings growing faster or slower than revenue is not applicable in a standard growth equity framework. Regarding income, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the firm reinvests all available resources into research, development, and operations rather than returning capital to shareholders. The overall growth and income profile is characterized by positive revenue expansion in a capital-intensive industry where immediate income generation is absent, requiring investors to rely on revenue trajectories and cash reserves rather than current profitability or dividend income for return expectations.